Skip to main content

United Therapeutics Constructs Ovarian Cancer Research Lab

Published 10/23/2003

United Therapeutics will construct a 40,000-sf ovarian cancer research lab and pharmaceutical manufacturing building adjacent to its headquarters in Silver Spring, Md. The $15-million lab is part of a 190,000-sf biotechnology campus planned by United Therapeutics. The new facility will manufacture OvaRex, an alternative to chemotherapy, in bulk for shipping to third-party manufacturers that will form it into pills.